中文产业新闻评分58Chinese source
恒瑞医药将口服GLP-1/GIP双受体激动剂HRS-1596在大中华区以外全球权益授权给诺和诺德
26亿美元！恒瑞GLP-1/GIP产品授权诺和诺德
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
26亿美元！恒瑞GLP-1/GIP产品授权诺和诺德
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.